TOPSOFT BLUE EAST

Glavne informacije

  • Zaščiteno ime:
  • TOPSOFT BLUE EAST
  • Uporabi za:
  • ljudje
  • Vrsta medicine:
  • Medicinski pripomoček

Dokumentov

Lokalizacija

  • Na voljo v:
  • TOPSOFT BLUE EAST
    Slovenija
  • Jezik:
  • slovenščina

Drugi podatki

Stanje

  • Source:
  • Ecolab
  • Številka dovoljenja:
  • 115766E
  • Zadnja posodobitev:
  • 12-03-2018

Glavnih Značilnosti Zdravila

TOPSOFT BLUE EAST

VARNOSTNI LIST

Ime proizvoda

TOPSOFT BLUE EAST

V skladu z Uredbo (ES) št. 1907/2006 (REACH), Priloga II (453/2010) - Evropa

:

1.1 Identifikator izdelka

1.3 Podrobnosti o dobavitelju varnostnega lista

1.2 Pomembne identificirane uporabe snovi ali zmesi in odsvetovane uporabe

Navedene uporabe

ODDELEK 1: Identifikacija snovi/zmesi in družbe/podjetja

Šifra proizvoda

:

Odsvetujejo se načini uporabe

1.4 Telefonska številka za nujne primere

Nacionalno posvetovalno telo/Center za zastrupitve

Nega perila (mehčalo/škrobilo). Avtomatski postopek

Nega perila (mehčalo/škrobilo). Polavtomatski postopek

Ni znano.

Ecolab d.o.o.

Vajngerlova 4

SI-2000 Maribor

Slovenija

Tel.: +386 (0)2 42 93 100

Št. faksa: +386 (0)2 42 93 152

office.maribor@ecolab.com

:

Proizvajalec/ Distributer/

Uvoznik

115766E

Uporaba proizvoda

:

Mehčalo za perilo

Proizvod je samo za profesionalno uporabo.

Proizvajalec/ Distributer/ Uvoznik

:

Številka telefona

Navodilo v primeru zdravstvene ogroženosti: nemudoma se posvetovati z osebnim

ali dežurnim zdravnikom, le v primeru življenjske ogroženosti poklicati 112.

:

Številka telefona

Tel.: +386 (0)2 42 93 100 (Uradne ure ob delavnikih: 8:00 – 15:00)

Verzija

: 1

Razvrstitev

Ni razvrščeno.

:

Glej Oddelek 11 za podrobnejše podatke o učinkih na zdravje in simptomih.

Razvrstitev skladno z Uredbo (ES) 1272/2008 [CLP/GHS]

ODDELEK 2: Ugotovitev nevarnosti

2.1 Razvrstitev snovi ali zmesi

Opredelitev izdelka

:

Zmes

Glej Oddelek 16 za celotno besedilo zgoraj navedenih stavkov R ali H.

Razvrstitev v skladu z Direktivo 1999/45/ES [DSD]

Proizvod ni razvrščen kot nevaren v skladu z Direktivo 1999/45/ES in njenimi dopolnitvami.

2.2 Elementi etikete

Stavki o nevarnosti

:

Previdnostni stavki

Dodatni elementi etikete

:

Varnostni list na voljo na zahtevo.

Ni razvrščeno.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Datum izdaje/Datum

revidirane izdaje

:

1/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 2: Ugotovitev nevarnosti

:

Ostale nevarnosti, ki

nimajo vpliva na

razvrstitev

2.3 Druge nevarnosti

Ni primerno.

Mejne vrednosti izpostavitve pri delu, če so na voljo, so navedene v oddelku 8.

Proizvod ne vsebuje dodatnih sestavin, ki bi bile, glede na trenutno znane podatke, ki so na voljo dobavitelju in v

primernih koncentracijah, razvrščene kot zdravju ali okolju nevarne in ki bi jih bilo potrebno navajati v tem oddelku.

ODDELEK 3: Sestava/podatki o sestavinah

[1] Snov razvrščena kot nevarna za zdravje ali okolje

[2] Snov za katero obstajajo mejne vrednosti za poklicno izpostavljenost

[3] Snov izpolnjuje merila za PBT skladno z Uredbo (ES) št. 1907/2006, priloga XIII.

[4] Snov izpolnjuje merila za vPvB skladno z Uredbo (ES) št. 1907/2006, priloga XIII.

[5] Snov, ki vzbuja enakovredno zaskrbljenost

Identifikatorji

67/548/EGS

Ime ali trgovsko ime

izdelka/snovi

Glej Oddelek 16 za

celotno besedilo

zgoraj navedenih R

stavkov

%

Tip

Uredba (ES) št.

1272/2008 [CLP]

Razvrstitev

Glej Oddelek 16 za

celotno besedilo

zgoraj navedenih

stavkov o nevarnosti

H.

TEA-esterkvati

REACH #:

01-2119463889-16

EC: 295-344-3

CAS: 91995-81-2

5 - <10

Xi; R36/38

Skin Irrit. 2, H315

Eye Irrit. 2, H319

propan-2-ol

REACH #:

01-2119457558-25

EC: 200-661-7

CAS: 67-63-0

Indeks: 603-117-00-0

1 - <5

F; R11

Xi; R36

Flam. Liq. 2, H225

Eye Irrit. 2, H319

STOT SE 3, H336

[1] [2]

Zmesi

3.2

Usta sprati z vodo. Če je snov bila zaužita in je ponerečenec pri zavesti, dajati

manjše količine vode za pitje. Ne sprožiti bruhanja, razen po navodilih zdravniškega

osebja. Če se pojavijo simptomi, poiskati zdravniško pomoč.

Stik s kožo

Oči takoj izpirati z obilo vode, občasno dvigniti zgornjo in spodnjo veko. Preveriti, ali

ima ponesrečenec kontaktne leče in jih odstraniti . Če se pojavi draženje, poiskati

zdravniško pomoč.

Onesnažen predel kože izprati z obilo vode. Odstraniti onesnažena oblačila in

obutev. Če se pojavijo simptomi, poiskati zdravniško pomoč.

4.1 Opis ukrepov za prvo pomoč

Prenesti ponesrečenca na svež zrak in ga pustiti počivati v položaju, ki olajša

dihanje. Če se pojavijo simptomi, poiskati zdravniško pomoč.

Zaužitje

Vdihavanje

Stik z očmi

:

:

:

:

Zaščita osebja za prvo

pomoč

:

ODDELEK 4: Ukrepi za prvo pomoč

4.2 Najpomembnejši simptomi in učinki, akutni in zapozneli

Do ukrepanja ne bo prišlo, če ima za posledico osebno tveganje ali osebje ni

predhodno ustrezno šolano.

Datum izdaje/Datum

revidirane izdaje

:

2/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 4: Ukrepi za prvo pomoč

Opombe za zdravnika

Zdraviti simptomatično. Pri zaužitju ali vdihavanju večjih količin, takoj poklicati

specialista za ravnanje v primeru zastrupitev.

:

Posebno ravnanje

Potencialno akutni vplivi na zdravje

Vdihavanje

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

:

Zaužitje

Stik s kožo

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

:

Stik z očmi

Znaki/simptomi prekomerne izpostavljenosti

Stik s kožo

Zaužitje

Vdihavanje

Ni specifičnih podatkov.

Ni specifičnih podatkov.

Ni specifičnih podatkov.

:

:

:

Stik z očmi

:

Ni specifičnih podatkov.

4.3 Navedba kakršne koli takojšnje medicinske oskrbe in posebnega zdravljenja

Ni specifičnega zdravljenja.

:

V primeru požara, evakuirati območje. Do ukrepanja ne bo prišlo, če ima za

posledico osebno tveganje ali osebje ni predhodno ustrezno šolano.

Nevarni produkti

izgorevanja

Nevarnosti zaradi snovi ali

zmesi.

Razkrojni produkti lahko vsebujejo naslednje snovi:

ogljikov dioksid

ogljikov monoksid

Pri požaru ali segrevanju, se tlak poveča in posoda lahko poči.

Gasilci morajo nositi primerno zaščitno opremo in samostojni dihalni aparat (SCBA)

z masko, ki pokriva celoten obraz in ima pozitiven tlak.

Navedba posebne

varovalne opreme za

gasilce

V primeru požara uporabiti razpršeno vodo (meglica), peno, suha gasilna sredstva

ali CO2.

5.1 Sredstva za gašenje

:

:

:

Ni znano.

Ustrezna sredstva za

gašenje

:

Neustrezna sredstva za

gašenje

:

ODDELEK 5: Protipožarni ukrepi

5.2 Posebne nevarnosti v zvezi s snovjo ali zmesjo

5.3 Nasvet za gasilce

Posebni previdnostni

ukrepi za gasilce

:

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.1 Osebni varnostni ukrepi, zaščitna oprema in postopki v sili

Za osebje. ki ni nujno

:

Za reševalce

:

Do ukrepanja ne bo prišlo, če ima za posledico osebno tveganje ali osebje ni

predhodno ustrezno šolano. Preprečiti dostop odvečnim in nezaščitenim osebam.

Poskusite se izogniti stiku ali hoji preko razlitega materiala. Nositi ustrezno osebno

zaščitno opremo.

Če so pri rokovanju z razlitjem zahtevana specialna oblačila, upoštevati podatke o

primernih in neprimernih materialih v Oddelku 8. Glej tudi informacije pod "Za

neizučeno osebje".

Datum izdaje/Datum

revidirane izdaje

:

3/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 6: Ukrepi ob nenamernih izpustih

6.2 Okoljevarstveni ukrepi

Zaustaviti razlitje, če to ne predstavlja tveganja. Odmakniti embalažo z mesta

razlitja. Preprečiti iztekanje v kanalizacijo, vodotoke, kleti ali zaprte prostore.

Sperite razlitja v obrat za obdelavo odpadnih vod ali ravnajte kot sledi. Zadržati in

zbrati razlit material z nevnetljivimi absorpcijskimi materiali, npr. peskom, prstjo,

vermikulitom, diatomejsko zemljo, in namestiti v embalažo za odstranjevanje v

skladu s predpisi.

Preprečiti, da bi se razlit oz. razsut tovor razširil; preprečiti stik s tlemi, vodotoki,

cestno kanalizacijo in odplakami. Če je prišlo do onesnaženja okolja (kanalizacije,

vodotokov, tal ali zraka), obvestiti pristojne službe.

Obsežno razlitje

:

Zaustaviti razlitje, če to ne predstavlja tveganja. Odmakniti embalažo z mesta

razlitja. Če je topno v vodi, razredčiti z vodo in pobrisati. Po drugi strani, oziroma če

ni topno v vodi, vsrkati z inertno suho snovjo in namestiti v ustrezno embalažo za

odstranjevanje odpadkov.

Majhno razlitje

:

6.3 Metode in materiali za zadrževanje in čiščenje

6.4 Sklicevanje na druge

oddelke

Glej Oddelek 1 za podatke o kontaktu za nujne primere.

Glej Oddelek 8 za podatke o ustrezni zaščitni opremi.

Glej Oddelek 13 za podatke o dodatni obdelavi odpadkov.

:

:

Skladiščiti med sledečima temperaturama: 5 do 40°C (41 do 104°F). Skladiščiti

skladno z lokalno zakonodajo. Skladiščiti v originalni embalaži, zaščiteno pred

direktno sončno svetlobo v suhem, hladnem in dobro prezračevanem prostoru,

ločeno od nezdružljivih snovi (glej Oddelek 10) ter hrane in pijače. Do uporabe

hraniti posodo tesno zaprto in zatesnjeno. Odprto embalažo previdno zatesniti in

držati v pokončnem položaju, da se prepreči iztekanje. Ne hraniti v neoznačeni

embalaži. S primernim ravnanjem preprečiti onesnaževanje okolja.

ODDELEK 7: Ravnanje in skladiščenje

Informacije v tem oddelku vsebujejo splošne nasvete in napotke. Glede specifične uporabe je za podatke, ki so na

voljo v scenariju(ih) izpostavljenosti, potrebno upoštevati seznam identificiranih uporab v Oddelku 1.

7.1 Varnostni ukrepi za varno ravnanje

Zaščitni ukrepi

:

Nasvet glede splošne

poklicne higiene

:

7.2 Pogoji za varno

skladiščenje, vključno z

nezdružljivostjo

7.3 Posebne končne uporabe

Nositi ustrezno osebno zaščitno opremo. (Glej Oddelek 8)

Pred jedjo, pitjem ali kajenjem si je potrebno umiti roke in obraz. Glej Oddelek 8 za

dodatne podatke glede higienskih ukrepov.

:

Razred skladiščenja

:

Rešitve, specifične za

industrijsko panogo

:

Ni primerno dokler ni na razpolago scenarijev izpostavljenosti za surovine.

Ni primerno dokler ni na razpolago scenarijev izpostavljenosti za surovine.

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

8.1 Parametri nadzora

Mejne vrednosti izpostavitve pri delu

Datum izdaje/Datum

revidirane izdaje

:

4/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 8: Nadzor izpostavljenosti/osebna zaščita

Varovanje rok

(EN 374)

Če se na osnovi ocene tveganja ugotovi, je potrebno uporabljati ustrezno

nameščen respirator s prečiščevanjem zraka ali respirator z dovodom zraka, ki je

skladen z odobrenim standardom. Izbira respiratorja naj temelji na znanih in

pričakovanih nivojih izpostavitve, nevarnosti proizvoda in delovnih omejitvah

respiratorja.

Ni posebnih priporočil.

Ni posebnih priporočil.

Zaščitoza oči/obraz

(EN 166)

Zaščita dihal

(EN 143, 14387)

:

:

:

Varovanje kože

Osebno zaščitno opremo za telo je potrebno izbrati na podlagi vrste dela, ki se

izvaja, in tveganj, ki so prisotna. To opremo mora pred ravnanjem s tem

proizvodom odobriti strokovnjak.

:

Nadzor izpostavljenosti

okolja

:

Emisije iz prezračevanja ali delovne procesne opreme je potrebno preveriti, da se

zagotovi skladnost z zahtevami zakonodaje o varovanju okolja. V nekaterih

primerih bodo za znižanje emisij na sprejemljivo raven potrebne naprave za

čiščenje hlapov, filtri ali inženirske modifikacije na procesni opremi.

Ustrezen tehnično-

tehnološki nadzor

:

Posebno prezračevanje ni potrebno. Dobro splošno prezračevanje naj bi zadoščalo

za uravnavanje izpostavitve delavcev nečistočam v zraku. Če proizvod vsebuje

sestavine z mejnimi vrednostmi izpostavitve, je potrebno delovni proces fizično

omejiti, prezračevati in zagotavljati, da so izpostavitve delavcev pod priporočenimi

ali predpisanimi mejnimi vrednostmi.

Po ravnanju s kemikalijami ter pred jedjo, kajenjem, uporabo stranišča in ob koncu

delovnega cikla, si temeljito umiti roke, podlakti in obraz. Primerno tehniko je

potrebno uporabiti za odstranitev potencialno onesnaženih oblačil. Oprati

onesnažena oblačila pred ponovno uporabo. Zagotoviti primerno bližino priprave

za izpiranje oči in prhe za nujne primere.

8.2 Nadzor izpostavljenosti

Higienski ukrepi

:

Za zmesi ni na razpolago DNEL vrednosti.

Predvidena koncentracija brez učinka (PNEC)

Za zmesi ni na razpolago PNEC vrednosti.

Izpeljana raven učinka (DNEL)

Osebni zaščitni ukrepi

Zaščita telesa

(EN 14605)

:

Druga zaščita za kožo

Toplotno nevarnostjo

:

Pred postopkom se mora na podlagi dela, ki se ga opravlja in z njim povezanih

tveganj, izbrati primerno obutev in morebitne dodatne ukrepe za zaščito kože, ki jih

odobri strokovnjak.

Ni primerno.

Ime ali trgovsko ime izdelka/snovi

Mejne vrednosti izpostavljenosti

propan-2-ol

Pravilnik o varovanju delavcev pred tveganji zaradi

izpostavljenosti kemičnim snovem pri delu (Slovenija,

12/2010).

MV: 500 mg/m³ 8 ur.

MV: 200 ppm 8 ur.

KTV: 2000 mg/m³, 4 krat na izmeno, 15 minut.

KTV: 800 ppm, 4 krat na izmeno, 15 minut.

Datum izdaje/Datum

revidirane izdaje

:

5/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 9: Fizikalne in kemijske lastnosti

Fizikalno stanje

Tališče/ledišče

Začetno vrelišče in območje vrelišča

Parni tlak

Relativna gostota

Parna gostota

Topnost

Tekočina.

0.998

Lahko topno v naslednjih snoveh: hladni vodi in vroči vodi.

Po parfumu.

Vonj

pH

Modra. [svetlo]

Barva

Hitrost izparevanja

Temperatura samovžiga

Plamenišče

> 100°C

2.5 [Konc. (%w/w): 100%]

Prag vonja

Porazdelitveni koeficient: n-

oktanol/voda

Eksplozivne lastnosti

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

:

Brez.

Oksidativne lastnosti

:

9.1 Podatki o osnovnih fizikalnih in kemijskih lastnostih

Izgled

9.2 Drugi podatki

Čas gorenja

Stopnja gorenja

:

:

Temperatura razkroja

:

Ni dodatnih podatkov.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno in/ali ni določeno za zmesi.

Ni primerno.

Ni primerno in/ali ni določeno za zmesi.

Viskoznost

:

Zgornje/

spodnje meje vnetljivosti ali eksplozivnosti

:

Ni primerno in/ali ni določeno za zmesi.

Vnetljivost (trdno, plinasto)

:

Ni primerno in/ali ni določeno za zmesi.

10.4 Pogoji, ki se jim je

treba izogniti

Ni specifičnih podatkov.

Proizvod je stabilen.

10.2 Kemijska stabilnost

:

:

10.5 Nezdružljivi materiali

:

10.3 Možnost poteka

nevarnih reakcij

:

Pri normalnih pogojih skladiščenja in uporabe do nevarnih reakcij ne bo prihajalo.

ODDELEK 10: Obstojnost in reaktivnost

10.1 Reaktivnost

:

Konkretnih podatkov o preskusih v zvezi z reaktivnostjo tega izdelka ali njegovih

sestavin ni na razpolago.

Rahlo reaktivno ali nezdružljivo z naslednjimi snovmi: alkalijami.

Nereaktivno ali združljivo z naslednjimi snovmi: organskimi snovmi, kovine, kislinami

in vlaga.

Datum izdaje/Datum

revidirane izdaje

:

6/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 10: Obstojnost in reaktivnost

10.6 Nevarni produkti

razgradnje

Pri normalnih pogojih skladiščenja in uporabe ne bi smelo prihajati do nevarnih

razkrojnih produktov.

:

Potencialno akutni vplivi na zdravje

Vdihavanje

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

:

Zaužitje

Stik s kožo

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

:

Stik z očmi

Akutna strupenost

propan-2-ol

LC50 Vdihavanje Para

Podgana

30 mg/L

4 ur

LD50 Dermalno

Kunec

12870 mg/kg

LD50 Oralno

Podgana

4710 mg/kg

Ime ali trgovsko ime

izdelka/snovi

Rezultat

Vrste

Odmerek

Izpostavljenost

Rakotvornost

Mutagenost

Teratogenost

Strupenost za razmnoževanje

Simptomi, ki izvirajo iz fizikalnih, kemičnih in toksikoloških značilnosti

Vdihavanje

Ni specifičnih podatkov.

:

Dražilnost/Jedkost

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Povzroča preobčutljivost

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

ODDELEK 11: Toksikološki podatki

11.1 Podatki o toksikoloških učinkih

Ocene akutne strupenosti

Ni določeno za zmesi.

SPECIFIČNA STRUPENOST ZA CILJNE ORGANE (STOT) – ENKRATNA IZPOSTAVLJENOST

STOT – ponavljajoča se izpostavljenost

Ime ali trgovsko ime izdelka/snovi

Kategorija

Nevarnost pri vdihavanju

Način

izpostavljenosti

Ciljni organi

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

propan-2-ol

Kategorija 3

Ni primerno.

Narkotični učinki

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Podatki o možnih načinih

izpostavljenosti

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Datum izdaje/Datum

revidirane izdaje

:

7/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 11: Toksikološki podatki

Potencialno kronični vplivi na zdravje

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Splošno

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Rakotvornost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Mutagenost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Teratogenost

:

Učinek na razvoj

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Učinki na plodnost

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Stik s kožo

Zaužitje

Ni specifičnih podatkov.

Ni specifičnih podatkov.

:

:

Stik z očmi

:

Ni specifičnih podatkov.

Zapozneli in takojšnji učinki ter kronični učinki po kratkodobni in dolgodobni izpostavljenosti

Kratkotrajna izpostavljenost

Dolgotrajna izpostavljenost

Možni neposredni učinki

:

Možni zapozneli učinki

:

Možni neposredni učinki

:

Možni zapozneli učinki

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Drugi podatki

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

ODDELEK 12: Ekološki podatki

LogP

ow

BCF

Potencialno

12.3 Zmožnost kopičenja v organizmih

Ime ali trgovsko ime

izdelka/snovi

propan-2-ol

0.05

nizko

12.1 Strupenost

propan-2-ol

Akutni LC50 9640 mg/L

Ribe

96 ur

Ime ali trgovsko ime

izdelka/snovi

Vrste

Rezultat

Izpostavljenost

12.2 Obstojnost in razgradljivost

Zaključek/Povzetek

:

V primeru izpusta kislih ali alkalnih proizvodov v naprave za čiščenje odplak, je

potrebno paziti, da je pH odplak med 6 in 10, saj nihanja pH lahko povzročijo motnje

v delovanju biološke čistilne naprave. Prednost ima lokalna zakonodaja s področja

odplak. V skladu z zahtevami evropskih zakonodajnih standardov za detergente

82/242/EEC (neionske površinsko aktivne snovi) in 82/243/EEC (anionske

površinsko aktivne snovi) so površinsko aktivne snovi, vsebovane v proizvodu,

povprečno najmanj 90% biorazgradljive.

Odstranljivost: Celokupne organske komponente se v čistilni napravi odstranijo v

vrednosti več kot 80%.

12.4 Mobilnost v tleh

Zaključek/Povzetek

:

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

Datum izdaje/Datum

revidirane izdaje

:

8/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 12: Ekološki podatki

12.6 Drugi škodljivi učinki

Ni znanih značilnih učinkov ali kritičnih nevarnosti.

PBT

:

Ni primerno.

vPvB

:

Ni primerno.

12.5 Rezultati ocene PBT in vPvB

:

Porazdelitveni koeficient

prst/voda (K

OC

)

:

Ni določeno za zmesi.

Mobilnost

:

Ni določeno za zmesi.

Evropski katalog odpadkov (EWC)

Glede na trenutno znanje dobavitelja, ta izdelek ni nevaren odpadek v skladu z

določili v EU direktivi 91/689/EC.

Nevarni odpadki

:

Kjerkoli je možno, se je potrebno izogniti nastajanju odpadkov, oziroma jih zmanjšati

na najmanjšo možno raven. Prazne posode ali podloge lahko zadržijo ostanke

proizvoda. Vsebina in embalaža morata biti varno odstranjeni. Znatnih količin

odpadnih ostankov proizvoda se ne sme spuščati v kanalizacijo, ampak jih je

potrebno obdelati v ustreznih čistilnih napravah. Preostanke in proizvode, ki se jih

ne da reciklirati, odstrani pooblaščeno podjetje za odstranjevanje odpadkov.

Odstranjevanje tega proizvoda, raztopin in kakršnih koli stranskih proizvodov mora

vedno potekati v skladu z zahtevami predpisov o zaščiti okolja in odstranjevanju

odpadkov oz. katerih koli drugih predpisov. Preprečiti, da bi se razlit oz. razsut tovor

razširil; preprečiti stik s tlemi, vodotoki, cestno kanalizacijo in odplakami.

:

Metode odstranjevanja

ODDELEK 13: Odstranjevanje

Informacije v tem oddelku vsebujejo splošne nasvete in napotke. Glede specifične uporabe je za podatke, ki so na

voljo v scenariju(ih) izpostavljenosti, potrebno upoštevati seznam identificiranih uporab v Oddelku 1.

13.1 Metode ravnanja z odpadki

Proizvod

Pakiranje

Šifra odpadka

Oznaka odpadka

Metode odstranjevanja

:

Posebni previdnostni

ukrepi

:

20 01 30

čistila, ki niso zajeta v 20 01 29

Kjerkoli je možno, se je potrebno izogniti nastajanju odpadkov, oziroma jih zmanjšati

na najmanjšo možno raven. Odpadno embalažo je potrebno reciklirati.

Vsebina in embalaža morata biti varno odstranjeni. Prazne posode ali podloge

lahko zadržijo ostanke proizvoda. Preprečiti, da bi se razlit oz. razsut tovor razširil;

preprečiti stik s tlemi, vodotoki, cestno kanalizacijo in odplakami.

Not regulated.

Ni predmet predpisov.

Ni predmet predpisov.

Not regulated.

ODDELEK 14: Podatki o prevozu

ADR/RID

IMDG

IATA

14.1 UN številka

14.2 UN Uradno

ime blaga

14.3 Razredi

nevarnosti

prevoza

ADN/ADNR

Datum izdaje/Datum

revidirane izdaje

:

9/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 14: Podatki o prevozu

14.4 Embalažna

skupina

14.5 Okolju

nevarno

14.6 Posebni

previdnostni

ukrepi za

uporabnika

14.7 Prevoz v razsutem

stanju v skladu s Prilogo II

k MARPOL 73/78 in

Kodeksom IBC

:

Ni primerno.

Brez.

Brez.

None.

None.

Državni predpisi

Drugi predpisi EU

Ni primerno.

Priloga XVII - Omejitve

proizvodnje, dajanja v

promet in uporabe

nekaterih nevarnih snovi,

pripravkov in izdelkov

:

ODDELEK 15: Zakonsko predpisani podatki

15.1 Predpisi/zakonodaja o zdravju, varnosti in okolju, specifični za snov ali zmes

Uredba ES (ES) št 1907/2006 (REACH)

Priloga XIV - Seznam snovi, ki so predmet avtorizacije

15.2 Ocena kemijske

varnosti

Izdelek vsebuje snovi, za katere se še vedno zahtevajo ocene kemijske varnosti.

Snovi, ki vzbujajo zelo veliko zaskrbljenost

:

Nobene od sestavin ni na seznamu.

≥5 - <15% kationski tenzidi

Vsebuje dišave: (Benzyl Salicylate, Hexyl Cinnamal, Butylphenyl Methylpropional, S8013-90-9, Linalool,

Coumarin, Limonene, Alpha-Isomethyl Ionone)

Navedba sestavin v skladu z Uredbo o detergentih 648/2004/EC:

Slovenija

Prikazuje informacijo, ki se je spremenila od prejšnje izdaje.

ODDELEK 16: Drugi podatki

Okrajšave in akronimi

:

ADN = Evropski sporazum o mednarodnem prevozu nevarnih snovi po celinskih

vodah/po Renu

ADR = Evropski sporazum o mednarodnem cestnem prevozu nevarnega blaga

ATE = ocena akutne strupenosti

BCF = biokoncentracijski faktor

CLP = Uredba (ES) št. 1272/2008 o razvrščanju, označevanju in pakiranju snovi ter

zmesi

DNEL = Izpeljana raven brez učinka

DPD = Direktiva Sveta EU [1999/45/EC] o razvrščanju, pakiranju in označevanju

Datum izdaje/Datum

revidirane izdaje

:

10/11

28 Oktober 2013

TOPSOFT BLUE EAST

ODDELEK 16: Drugi podatki

28 Oktober 2013

Datum tiskanja

Datum izdaje/ Datum

revidirane izdaje

Verzija

Za posredovane podatke verjamemo, da so pravilni glede na formulacijo uporabljeno za proizvodnjo izdelka v

državi porekla. V primeru, da se podatki, standardi ali zakonodaja spremenijo, kakor tudi pogoji uporabe ter

rokovanja, ki so izven našega nadzora, NE DAJEMO NOBENEGA JAMSTVA, IZRAŽENEGA ALI NAZNAČENEGA,

GLEDE CELOVITOSTI ALI NEOKRNJENE TOČNOSTI NAVEDENIH PODAKOV.

Obvestilo bralcu

Datum prejšnje izdaje

:

:

:

:

Celotno besedilo okrajšanih

stavkov R

:

R11- Lahko vnetljivo.

R36- Draži oči.

R36/38- Draži oči in kožo.

R67- Hlapi lahko povzročijo zaspanost in omotico.

F - Lahko vnetljivo

Xi - Dražilno

:

Celotno besedilo razvrstitev

[DSD/DPD]

28 Oktober 2013

Ni prejšnje validacije

Celotno besedilo okrajšanih

stavkov H

:

nevarnih pripravkov

EC = evropska komisija

EUH = CLP - specifičen stavek nevarnosti

IATA = Mednarodno združenje letalskih prevoznikov

IBC = vsebnik IBC

IMDG = Mednarodni kodeks o prevozu nevarnega blaga po morju

LogPow = logaritem porazdelitvenega koeficienta oktanol/voda

MARPOL 73/78 = Mednarodna konvencija o preprečevanju onesnaževanja morja z

ladij, 1973, in njen Protokol iz leta 1978

OEL = mejna vrednost za poklicno izpostavljenost

PBT = Obstojen, bioakumulativen in strupen

PNEC = predvidena koncentracija brez učinka

REACH = Registracija, Evalvacija, Avtorizacija in omejevanje Kemikalij [Uredba (ES)

št. 1907/2006]

RID = Pravilnik o mednarodnem železniškem prevozu nevarnega blaga

REACH # = Registracijska številka REACH

vPvB = zelo obstojen in zelo bioakumulativen

Postopek, po katerem se je določilo razvrstitev po uredbi (ES) št. 1272/2008 [CLP/GHS]

Razvrstitev

Utemeljitev

Ni razvrščeno.

Celotno besedilo razvrstitev

[CLP/GHS]

:

H225

Lahko vnetljiva tekočina in hlapi.

H315

Povzroča draženje kože.

H319

Povzroča hudo draženje oči.

H336

Lahko povzroči zaspanost ali omotico.

Eye Irrit. 2, H319

HUDA POŠKODBA OČI/DRAŽENJE OČI - Kategorija 2

Flam. Liq. 2, H225

VNETLJIVA TEKOČINA - Kategorija 2

Skin Irrit. 2, H315

JEDKOST ZA KOŽO/DRAŽENJE KOŽE - Kategorija 2

STOT SE 3, H336

SPECIFIČNA STRUPENOST ZA CILJNE ORGANE

(STOT) – ENKRATNA IZPOSTAVLJENOST [Narkotični

učinki] - Kategorija 3

Datum izdaje/Datum

revidirane izdaje

:

11/11

28 Oktober 2013

21-11-2018

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Risk for animal and human health related to the presence of dioxins and dioxin-like PCBs in feed and food

Published on: Tue, 20 Nov 2018 The European Commission asked EFSA for a scientific opinion on the risks for animal and human health related to the presence of dioxins (PCDD/Fs) and DL‐PCBs in feed and food. The data from experimental animal and epidemiological studies were reviewed and it was decided to base the human risk assessment on effects observed in humans and to use animal data as supportive evidence. The critical effect was on semen quality, following pre‐ and postnatal exposure. The critical s...

Europe - EFSA - European Food Safety Authority Publications

17-11-2018

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Safety evaluation of the food enzyme endo‐1,4‐β‐xylanase from a genetically modified Aspergillus oryzae (strain NZYM‐FA)

Published on: Fri, 16 Nov 2018 The food enzyme is an endo‐1,4‐β‐xylanase (EC 3.2.1.8) produced with a genetically modified strain of Aspergillus oryzae by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This xylanase is intended to be used in baking and cereal‐based processes. Based on the proposed maximum use levels, dietary exposure to the food enzyme–total organic solids (TOS) was e...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐OC)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐a‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐OC by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels recommended, dietary exposure to the food enzyme–...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Safety evaluation of the food enzyme maltogenic amylase from a genetically modified Bacillus subtilis (strain NZYM‐SO)

Published on: Wed, 14 Nov 2018 The food enzyme maltogenic amylase (glucan 1,4‐α‐maltohydrolase; EC 3.2.1.133) is produced with a genetically modified Bacillus subtilis strain NZYM‐SO by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production microorganism and recombinant DNA. This maltogenic amylase is intended to be used in baking processes. Based on the maximum use levels, dietary exposure to the food enzyme–total organi...

Europe - EFSA - European Food Safety Authority Publications

15-11-2018

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Safety evaluation of the food enzyme acetolactate decarboxylase from a genetically modified Bacillus licheniformis (strain NZYM‐JB)

Published on: Wed, 14 Nov 2018 The food enzyme acetolactate decarboxylase (α‐acetolactate decarboxylase; EC 4.1.1.5) is produced with a genetically modified Bacillus licheniformis strain NZYM‐JB by Novozymes A/S. The genetic modifications do not give rise to safety concerns. The food enzyme is free from viable cells of the production organism and recombinant DNA. This acetolactate decarboxylase is intended to be used in distilled alcohol production and brewing processes. Residual amounts of total organi...

Europe - EFSA - European Food Safety Authority Publications

10-11-2018

Pest categorisation of Popillia japonica

Pest categorisation of Popillia japonica

Published on: Thu, 08 Nov 2018 00:00:00 +0100 The Panel on Plant Health performed a pest categorisation of Popillia japonica(Coleoptera: Scarabaeidae) for the EU. P. japonica is a distinguishable species listed in Annex IAII of Council Directive 2000/29/EC. It is native to Japan but established in the USA in the early 20th century. It spreads from New Jersey to most US states east of the Mississippi, some to the west and north into Canada. P. japonica feeds on over 700 plant species. Adults attack folia...

Europe - EFSA - European Food Safety Authority Publications

8-11-2018

Public Notification: Gold Max Blue contains hidden drug ingredient

Public Notification: Gold Max Blue contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Gold Max Blue, a product promoted and sold for sexual enhancement on various websites, including www.goldmaxblue.com, and possibly in some retail stores.

FDA - U.S. Food and Drug Administration

1-11-2018

Pest categorisation of Acrobasis pirivorella

Pest categorisation of Acrobasis pirivorella

Published on: Wed, 31 Oct 2018 00:00:00 +0100 The European Commission requested EFSA to conduct a pest categorisation of Acrobasis pirivorella (Lepidoptera: Pyralidae), a monophagous moth whose larvae exclusively feed on developing buds, flowers, and fruits of cultivated and wild Pyrus spp. A. pirivorella is a species with reliable methods available for identification. A. pirivorellaoccurs in north‐east Asia only, causing significant damage in cultivated pears. It is regulated in the EU by Council Direc...

Europe - EFSA - European Food Safety Authority Publications

30-10-2018

Pest categorisation of Sternochetus mangiferae

Pest categorisation of Sternochetus mangiferae

Published on: Mon, 29 Oct 2018 00:00:00 +0100 The European Commission requested EFSA to conduct a pest categorisation of Sternochetus mangiferae (Coleoptera: Curculionidae), a monophagous pest weevil whose larvae exclusively feed on mango seeds, whereas adults feed on mango foliage. S. mangiferae is a species with reliable methods available for identification. It is regulated in the EU by Council Directive 2000/29/EC where it is listed in Annex IIB as a harmful organism whose introduction into EU Protec...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. East Trading Corp. Issues Alert on Undeclared Sulfites In Fruits Du Sud Golden Seedless Raisins

P. EAST TRADING CORP. of Bronx, NY is recalling Fruits Du Sud Golden Seedless Raisins (Lot No. FDS T499/18) 30 lbs Box, because they contain undeclared SULFITES. People who have a severe sensitivity to sulfites run the risk of serious or life-threatening reactions if they consume these products.

FDA - U.S. Food and Drug Administration

16-10-2018

Pest categorisation of Melampsora farlowii

Pest categorisation of Melampsora farlowii

Published on: Mon, 15 Oct 2018 00:00:00 +0200 Following a request from the European Commission, the EFSA Panel on Plant Health performed a pest categorisation of Melampsora farlowii, a well‐defined and distinguishable fungus of the family Melampsoraceae. M. farlowii is the causal agent of a leaf and twig rust of hemlocks (Tsuga spp.) in eastern North America. The pathogen is regulated in Council Directive 2000/29/EC (Annex IAI) as a harmful organism whose introduction into the EU is banned. M. farlowii ...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Avian influenza overview May – August 2018

Avian influenza overview May – August 2018

Published on: Thu, 27 Sep 2018 00:00:00 +0200 Between 16 May and 15 August 2018, three highly pathogenic avian influenza (HPAI) A(H5N8) outbreaks in poultry establishments and three HPAI A(H5N6) outbreaks in wild birds were reported in Europe. Three low pathogenic avian influenza (LPAI) outbreaks were reported in three Member States. Few HPAI and LPAI bird cases have been detected in this period of the year, in accordance with the seasonal expected pattern of LPAI and HPAI. There is no evidence to date ...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

Modification of the existing maximum residue levels for potassium phosphonates in certain berries and small fruits

Modification of the existing maximum residue levels for potassium phosphonates in certain berries and small fruits

Published on: Tue, 18 Sep 2018 00:00:00 +0200 In accordance with Article 6 of Regulation (EC) No 396/2005, the applicant LTZ Augustenberg submitted a request to the competent national authority in Germany to modify the existing maximum residue levels (MRLs) for the active substance potassium phosphonates in raspberries, blackberries, currants, blueberries, gooseberries and elderberries. The data submitted in support of the request were found to be sufficient to derive MRL proposals for all crops under c...

Europe - EFSA - European Food Safety Authority Publications

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

14-9-2018

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s commitment to studying breast implant safety

Statement from Binita Ashar, M.D., of the FDA’s Center for Devices and Radiological Health on agency’s commitment to studying breast implant safety

FDA Statement on agency’s commitment to studying breast implant safety Short Title: FDA Statement on agency’s commitment to studying breast implant safety

FDA - U.S. Food and Drug Administration

13-9-2018

Use of next‐generation sequencing in microbial risk assessment

Use of next‐generation sequencing in microbial risk assessment

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Despite the ever increase in rigorous control and monitoring measures to assure safe food along the entire farm‐to‐fork chain, the past decade has also witnessed an increase in microbial food alerts. Hence, research on food safety and quality remain of utmost importance. Complementary, and at least as important, is the necessity to be able to assess the potential microbial risks along the food chain. Risk assessment relies on sound scientific data. Unfortuna...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Prizer-Painter Stove Works, Inc. recalls BlueStar and Big Chill Brand Gas Ranges and Wall Ovens

Prizer-Painter Stove Works, Inc. recalls BlueStar and Big Chill Brand Gas Ranges and Wall Ovens

Use of the convection oven fan during pre-heating or broiling can cause accumulated gas to ignite, posing a burn hazard to consumers when oven door is opened.

Health Canada

11-9-2018

Update of the Xylella spp. host plant database

Update of the Xylella spp. host plant database

Published on: Mon, 10 Sep 2018 00:00:00 +0200 Following a request from the European Commission, EFSA periodically updates the database on the host plants of Xylella spp. While previous editions of the database (2015 and 2016) dealt with the species Xylella fastidiosa only, this database version addresses the whole genus Xylella, including therefore both species X. fastidiosa and Xylella taiwanensis. The database now includes information on host plants of Xylella spp. retrieved from scientific literature...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Assessment of occupational and dietary exposure to pesticide residues

Assessment of occupational and dietary exposure to pesticide residues

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Plant protection products (PPPs) are pesticides containing at least one active substance that drives specific actions against pests (diseases). PPPs are regulated in the EU and cannot be placed on the market or used without prior authorisation. EFSA assesses the possible risks of the use of active substances to humans and environment. Member States decide whether or not to approve their use at EU level. Furthermore, Member States decide at national level on ...

Europe - EFSA - European Food Safety Authority Publications

8-8-2018

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves treatment for two rare types of non-Hodgkin lymphoma

FDA approves new drug for the treatment of adults with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy

FDA - U.S. Food and Drug Administration

31-7-2018

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

AuroMedics Pharma LLC Issues Voluntary Nationwide Recall of Piperacillin and Tazobactam for Injection 3.375 grams per vial, Due to Presence of Particulates Identified as Glass and Silicone Material

East Windsor, New Jersey, AuroMedics Pharma LLC is voluntarily recalling two lots of Piperacillin and Tazobactam for injection, USP 3.375 g (Piperacillin Sodium equivalent to 3 g of Piperacillin USP and Tazobactam Sodium equivalent to 0.375 g of Tazobactam USP. Each vial contains 7.05 mEq (162 mg) of Sodium) in a Single-Dose vial, to the hospital level. One vial from lot# PP0317012-A was found to contain particulate matter, identified as glass within the vial and another vial from lot# PP0317059-A was fo...

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

24-7-2018

FDA approves magnetic device system for guiding sentinel lymph node biopsies in certain patients with breast cancer

FDA approves magnetic device system for guiding sentinel lymph node biopsies in certain patients with breast cancer

FDA approves magnetic device system for guiding sentinel lymph node biopsies in certain patients with breast cancer

FDA - U.S. Food and Drug Administration

19-7-2018

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd recalls K9 Natural Frozen Chicken Feast Raw Pet Food 11lb bags

K9 Natural Ltd is voluntarily recalling K9 Natural Frozen Chicken Feast 11lb bags, batch number #150517, that were imported into the Canadian market in July 2017 because they have the potential to be contaminated with Listeria monocytogenes. No other K9 Natural products are affected in Canada.

Health Canada

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

22-5-2018

Porsche Cars Canada, Ltd. recalls My First Porsche - Wooden Car (in blue/black)

Porsche Cars Canada, Ltd. recalls My First Porsche - Wooden Car (in blue/black)

The wheels and axles of the toy car may come loose and detach, posing a choking hazard to young children.

Health Canada

17-5-2018

Intent to submit a marketing authorisation application for a veterinary medicinal product using the decentralised procedure with France as a Reference Member State (RMS).

Intent to submit a marketing authorisation application for a veterinary medicinal product using the decentralised procedure with France as a Reference Member State (RMS).

An applicant intending to submit a marketing authorisation application for a veterinary medicinal product using the decentralised procedure with France acting as RMS has to inform the Anses-ANMV at least 2 months in advance.

France - Agence Nationale du Médicament Vétérinaire

9-5-2018

Breast implants and anaplastic large cell lymphoma

Breast implants and anaplastic large cell lymphoma

Update on number of confirmed BIA-ALCL cases in Australia

Therapeutic Goods Administration - Australia

8-5-2018

What to Know When Buying or Using a Breast Pump

What to Know When Buying or Using a Breast Pump

Breast pumps are medical devices regulated by the U.S. Food and Drug Administration. They can be used to extract milk, maintain or increase a woman's milk supply, and relieve engorged breasts (among other indications). But, to protect mothers and their babies, there are important safety considerations to know before using one.

FDA - U.S. Food and Drug Administration

6-4-2018

5 Things to Know About Breast Implants

5 Things to Know About Breast Implants

The U.S. Food and Drug Administration regulates breast implants as medical devices. Learn about the risks of these products, and consider this advice.

FDA - U.S. Food and Drug Administration

14-12-2017

Marmex Corp Issues Voluntary Nationwide Recall Of Blue Pearl All Natural Male Enhancement Supplement, Due To Undeclared Sildenafil

Marmex Corp Issues Voluntary Nationwide Recall Of Blue Pearl All Natural Male Enhancement Supplement, Due To Undeclared Sildenafil

Orange, CA, Marmex Corp is voluntarily recalling All lots of Blue Pearl All Natural Male Enhancement Supplement, 500mg to the consumer level. FDA analysis has found the products to contain sildenafil.

FDA - U.S. Food and Drug Administration

30-10-2018

#DYK: Mammograms are still the best tool for breast cancer screening.  Check out @US_FDA’s information on the importance of choosing a certified mammography facility:  https://go.usa.gov/xPPpT  #MedicalDevice #BreastCancerAwarenessMonthpic.twitter.com/YaG

#DYK: Mammograms are still the best tool for breast cancer screening. Check out @US_FDA’s information on the importance of choosing a certified mammography facility: https://go.usa.gov/xPPpT  #MedicalDevice #BreastCancerAwarenessMonthpic.twitter.com/YaG

#DYK: Mammograms are still the best tool for breast cancer screening. Check out @US_FDA’s information on the importance of choosing a certified mammography facility: https://go.usa.gov/xPPpT  #MedicalDevice #BreastCancerAwarenessMonth pic.twitter.com/YaGqeGgrTH

FDA - U.S. Food and Drug Administration

26-10-2018

Men can also be diagnosed with breast cancer. Check out the @US_FDA’s information regarding breast cancer in men, available treatments and counseling options:  https://go.usa.gov/xPPpx  ) #MedicalDevice #BreastCancerAwarenessMonthpic.twitter.com/aZBjgCGsB

Men can also be diagnosed with breast cancer. Check out the @US_FDA’s information regarding breast cancer in men, available treatments and counseling options: https://go.usa.gov/xPPpx  ) #MedicalDevice #BreastCancerAwarenessMonthpic.twitter.com/aZBjgCGsB

Men can also be diagnosed with breast cancer. Check out the @US_FDA’s information regarding breast cancer in men, available treatments and counseling options: https://go.usa.gov/xPPpx  ) #MedicalDevice #BreastCancerAwarenessMonth pic.twitter.com/aZBjgCGsB1

FDA - U.S. Food and Drug Administration

24-10-2018

Stay informed of the most effective breast cancer screening options by checking out our consumer update warning against the use of thermography as mammogram substitute:  https://go.usa.gov/xPUA7  #FDA #MedicalDevice #BreastCancerAwarenessMonth

Stay informed of the most effective breast cancer screening options by checking out our consumer update warning against the use of thermography as mammogram substitute: https://go.usa.gov/xPUA7  #FDA #MedicalDevice #BreastCancerAwarenessMonth

Stay informed of the most effective breast cancer screening options by checking out our consumer update warning against the use of thermography as mammogram substitute: https://go.usa.gov/xPUA7  #FDA #MedicalDevice #BreastCancerAwarenessMonth

FDA - U.S. Food and Drug Administration

24-10-2018

It’s #BreastCancerAwarenessMonth and the @US_FDA is reminding patients and caregivers that thermography is not a substitute for mammograms.pic.twitter.com/XGJFHvut4x

It’s #BreastCancerAwarenessMonth and the @US_FDA is reminding patients and caregivers that thermography is not a substitute for mammograms.pic.twitter.com/XGJFHvut4x

It’s #BreastCancerAwarenessMonth and the @US_FDA is reminding patients and caregivers that thermography is not a substitute for mammograms. pic.twitter.com/XGJFHvut4x

FDA - U.S. Food and Drug Administration

21-10-2018

It’s concerning that many women who qualify for a mammogram don’t go for regular screening, in part due to common myths like mammograms “are painful” or “cause cancer.”  During this Breast Cancer Awareness month, I urge women to check the facts  https://g

It’s concerning that many women who qualify for a mammogram don’t go for regular screening, in part due to common myths like mammograms “are painful” or “cause cancer.” During this Breast Cancer Awareness month, I urge women to check the facts https://g

It’s concerning that many women who qualify for a mammogram don’t go for regular screening, in part due to common myths like mammograms “are painful” or “cause cancer.” During this Breast Cancer Awareness month, I urge women to check the facts https://go.usa.gov/xPnyD . pic.twitter.com/DGz5Xvquky

FDA - U.S. Food and Drug Administration

21-10-2018

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed h

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed h

We know that cancer is harder to find in women with dense breasts – some women may need other imaging tests. Breast density reporting is already required in some states. Expanding this nationwide will empower patients and providers to make more informed health decisions.

FDA - U.S. Food and Drug Administration

21-10-2018

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting  ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting ht

We’re now moving to update/modernize our oversight to capitalize on a # of important advances, including the increased use of digital imaging, revised screening recommendations from the @CDCgov and need for uniform nation-wide breast density reporting https://go.usa.gov/xPnyd .

FDA - U.S. Food and Drug Administration

21-10-2018

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%,

The MQSA was intended to address mammography quality concerns and it’s been a huge success. Image quality has improved, radiation dose has declined and equipment violations have all but disappeared. Today the 5-year breast cancer survival rate is 95%-99%, up from 84% in 1995.

FDA - U.S. Food and Drug Administration

21-10-2018

Also, while most of FDA’s women’s health initiatives are product specific, the #FDA plays an outsize role when it comes to mammography, which produces low-dose x-ray picture of the breast – an important tool to detect breast cancer in its early, most trea

Also, while most of FDA’s women’s health initiatives are product specific, the #FDA plays an outsize role when it comes to mammography, which produces low-dose x-ray picture of the breast – an important tool to detect breast cancer in its early, most trea

Also, while most of FDA’s women’s health initiatives are product specific, the #FDA plays an outsize role when it comes to mammography, which produces low-dose x-ray picture of the breast – an important tool to detect breast cancer in its early, most treatable stages. pic.twitter.com/aoYjsSEPrC

FDA - U.S. Food and Drug Administration

21-10-2018

Although I’ve been focusing on medical products, we're also advancing our food safety and nutrition work, such as our joint advice w/ EPA on making informed choices about eating fish for women who are pregnant, may become pregnant or are breastfeeding  ht

Although I’ve been focusing on medical products, we're also advancing our food safety and nutrition work, such as our joint advice w/ EPA on making informed choices about eating fish for women who are pregnant, may become pregnant or are breastfeeding ht

Although I’ve been focusing on medical products, we're also advancing our food safety and nutrition work, such as our joint advice w/ EPA on making informed choices about eating fish for women who are pregnant, may become pregnant or are breastfeeding https://go.usa.gov/xPnda . pic.twitter.com/nktV9BDAC3

FDA - U.S. Food and Drug Administration

18-10-2018

#FDA is committed to supporting women’s health. We know mammography is an important tool for detecting breast cancer in its early, most treatable stages and an excellent example of the meaningful and positive impact of medical device innovations

#FDA is committed to supporting women’s health. We know mammography is an important tool for detecting breast cancer in its early, most treatable stages and an excellent example of the meaningful and positive impact of medical device innovations

#FDA is committed to supporting women’s health. We know mammography is an important tool for detecting breast cancer in its early, most treatable stages and an excellent example of the meaningful and positive impact of medical device innovations

FDA - U.S. Food and Drug Administration

18-10-2018

THREAD: #FDA’s forthcoming proposal to update and modernize our mammography oversight is meant to capitalize on a number of important advances, including the need for more uniform, nation-wide breast density reporting:  https://go.usa.gov/xPRAm pic.twitte

THREAD: #FDA’s forthcoming proposal to update and modernize our mammography oversight is meant to capitalize on a number of important advances, including the need for more uniform, nation-wide breast density reporting: https://go.usa.gov/xPRAm pic.twitte

THREAD: #FDA’s forthcoming proposal to update and modernize our mammography oversight is meant to capitalize on a number of important advances, including the need for more uniform, nation-wide breast density reporting: https://go.usa.gov/xPRAm  pic.twitter.com/8cUIqr8l6x

FDA - U.S. Food and Drug Administration

17-10-2018

Mark Your Calendars: October 21 is Pink Ribbon Sunday! Wear pink to raise awareness about breast cancer and the value of mammograms:   http://go.usa.gov/xPkDE pic.twitter.com/IdHFDQ7dAW

Mark Your Calendars: October 21 is Pink Ribbon Sunday! Wear pink to raise awareness about breast cancer and the value of mammograms: http://go.usa.gov/xPkDE pic.twitter.com/IdHFDQ7dAW

Mark Your Calendars: October 21 is Pink Ribbon Sunday! Wear pink to raise awareness about breast cancer and the value of mammograms: http://go.usa.gov/xPkDE  pic.twitter.com/IdHFDQ7dAW

FDA - U.S. Food and Drug Administration

16-10-2018

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults:  https://go.usa.gov/xPNnH .pic.twitter.com/5mo0xuGCcK

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults: https://go.usa.gov/xPNnH .pic.twitter.com/5mo0xuGCcK

#FDAapproves new drug for the treatment of breast cancer with certain gene mutations for adults: https://go.usa.gov/xPNnH . pic.twitter.com/5mo0xuGCcK

FDA - U.S. Food and Drug Administration

13-10-2018

Get the facts about digital mammography:  https://go.usa.gov/xPkG7   BCAM18 #BreastCancer

Get the facts about digital mammography: https://go.usa.gov/xPkG7  BCAM18 #BreastCancer

Get the facts about digital mammography: https://go.usa.gov/xPkG7  BCAM18 #BreastCancer

FDA - U.S. Food and Drug Administration

26-9-2018

Today, the National Breast Implant Registry opened. This new registry, a collaboration between @ASPSMembers, implant manufacturers and #FDA, provides an important new platform for evaluating real world data on the safety and performance of breast implants

Today, the National Breast Implant Registry opened. This new registry, a collaboration between @ASPSMembers, implant manufacturers and #FDA, provides an important new platform for evaluating real world data on the safety and performance of breast implants

Today, the National Breast Implant Registry opened. This new registry, a collaboration between @ASPSMembers, implant manufacturers and #FDA, provides an important new platform for evaluating real world data on the safety and performance of breast implants https://bit.ly/2OU7wKX 

FDA - U.S. Food and Drug Administration

14-9-2018

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link:  https://go.usa.gov/xPg4C  #MedicalDevices

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link: https://go.usa.gov/xPg4C  #MedicalDevices

#FDA's Dr. Binita Ashar provides a statement on continuing the agency’s commitment to studying breast implant safety. To read the statement, click the link: https://go.usa.gov/xPg4C  #MedicalDevices

FDA - U.S. Food and Drug Administration

7-9-2018

Consumer story: Georgia and breast implant associated cancer

Consumer story: Georgia and breast implant associated cancer

Learn how to spot the warning signs for breast implant associated cancer in our new consumer story

Therapeutic Goods Administration - Australia

22-8-2018

BTVPUR (Merial)

BTVPUR (Merial)

BTVPUR (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 4)) - Centralised - 2-Monthly update - Commission Decision (2018)5630 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2231/II/10

Europe -DG Health and Food Safety

27-7-2018

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (bluebird bio (Germany) GmbH)

EU/3/14/1263 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human beta A-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5035 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/184/13/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (bluebird bio (Germany) GmbH)

EU/3/12/1091 (Active substance: Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human betaA-T87Q-globin gene) - Transfer of orphan designation - Commission Decision (2018)5032 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/146/12/T/01

Europe -DG Health and Food Safety

27-7-2018

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (bluebird bio (Germany) GmbH)

EU/3/12/1003 (Active substance: Autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ABCD1 cDNA) - Transfer of orphan designation - Commission Decision (2018)5033 of Fri, 27 Jul 2018 European Medicines Agency (EMA) procedure number: EMA/OD/009/12/T/01

Europe -DG Health and Food Safety

1-6-2018

BTVPUR AlSap 2-4 (Merial)

BTVPUR AlSap 2-4 (Merial)

BTVPUR AlSap 2-4 (Active substance: Bluetongue Virus Serotype 2 antigen - Bluetongue Virus Serotype 4 antigen) - Withdrawal (sunset clause) - No Commission Decision

Europe -DG Health and Food Safety

16-5-2018

BTVPUR AlSap 8 (Merial)

BTVPUR AlSap 8 (Merial)

BTVPUR AlSap 8 (Active substance: Bluetongue virus Serotype 8 Antigen) - Centralised - Withdrawal - Commission Decision (2018)3018 of Wed, 16 May 2018

Europe -DG Health and Food Safety

16-5-2018

BTVPUR AlSap 1 (Merial)

BTVPUR AlSap 1 (Merial)

BTVPUR AlSap 1 (Active substance: Bluetongue Virus Serotype 1 antigen) - Centralised - Withdrawal - Commission Decision (2018)3017 of Wed, 16 May 2018

Europe -DG Health and Food Safety

23-3-2018

EU/3/18/1998 (Blue-Reg Europe)

EU/3/18/1998 (Blue-Reg Europe)

EU/3/18/1998 (Active substance: Patidegib) - Orphan designation - Commission Decision (2018)1887 of Fri, 23 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/206/17

Europe -DG Health and Food Safety